Company profile: Lumora
1.1 - Company Overview
Company description
- Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lumora
iosBio
HQ: United Kingdom
Website
- Description: Provider of thermally stable oral vaccine platforms and services, offering vaccine manufacturing, distribution, and delivery. Its OraPro technology uses viral vectors to deliver capsule-based vaccines to the GI tract, enabling mucosal and systemic immunity without cold-chain storage. Products include OraPro and OraPro-Covid-19, an at-home oral vaccine targeting S and N proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iosBio company profile →
ITS Innovation
HQ: United Kingdom
Website
- Description: Provider of synthetic vaccines for mutating viruses using a T-cell vaccine platform that targets conserved viral antigens to direct immune responses, and of pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, designed to reduce body weight, liver fat, serum lipids, and address liver fat and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ITS Innovation company profile →
AN2 Therapeutics
HQ: United States
Website
- Description: Provider of boron chemistry–based drug discovery and clinical development for infectious diseases, including epetraborole, an oral therapy in development for chronic non-tuberculous mycobacterial lung disease targeting Mycobacterium avium complex, and conducting clinical trials to obtain regulatory approval for new medications for infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AN2 Therapeutics company profile →
Abionic
HQ: Switzerland
Website
- Description: Provider of point-of-care diagnostic solutions at the boundaries of medical technology, biotechnology and nanotechnology, including abioSCOPE for rapid, accurate results from a single drop of blood; PSP Sepsis Test using Pancreatic Stone Protein for early sepsis detection; saliva-based SARS-CoV-2 antigen test; aeroallergen specific IgE panel; ferritin test for iron deficiency; and cSOFA COVID-19 severity score for triage and management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abionic company profile →
Lumen Bioscience
HQ: United States
Website
- Description: Provider of biologic drug and vaccine development and manufacturing, leveraging a platform for rapid, cost-effective production. Pipeline includes biologic cocktails for C. difficile colitis, Covid-19 GI infection, and inflammatory bowel disease, a preclinical cardiometabolic program with Novo Nordisk, and a Phase 2 product candidate for traveler’s diarrhea backed by CARB-X and the Bill & Melinda Gates Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumen Bioscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lumora
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lumora
2.2 - Growth funds investing in similar companies to Lumora
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lumora
4.2 - Public trading comparable groups for Lumora
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →